tezepelumab

News

Relief for AZ, Amgen as FDA okays severe asthma hope tezepel...

The FDA has approved AstraZeneca and Amgen's severe asthma hope tezepelumab, exonerating the drugmakers' decision to press ahead with a regulatory filing despite a failed phase 3 trial.

News

ICER says Amgen's tezepelumab 'likely to be too expensive'

Amgen and AstraZeneca haven't won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but the ICER in the US maintains it will probably not

News

Amgen builds case for severe asthma drug tezepelumab

Amgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in patients who also have nasal polyps, a common complication of the

News

AZ, Amgen get speedy FDA review for asthma drug tezepelumab

The FDA has started a priority review of AstraZeneca and Amgen's severe asthma antibody tezepelumab, setting a date for a decision in the first quarter of 2022.

News

AZ trumpets tezepelumab data as filing for severe asthma loo...

AstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to file for approval in the first half of this year, with a broader indication than riv

News

AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trial

AstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a pair of positive clinical trials, but the failure of a third threatens to derail

Relief for AZ, Amgen as FDA okays severe asthma hope tezepel...

ICER says Amgen's tezepelumab 'likely to be too expensive'

Amgen builds case for severe asthma drug tezepelumab

AZ, Amgen get speedy FDA review for asthma drug tezepelumab

AZ trumpets tezepelumab data as filing for severe asthma loo...

AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trial

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

tezepelumab

Editor's Picks